Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Clynes, Raphael A., Towers, Terri L., Presta, Leonard G., Ravetch, Jeffrey V.·2000·Nature Medicine
DOI 10.1038/74704

Cited by (1,006)

Items 901–1,000 of 1,006

  1. An immune evasion mechanism with IgG4 playing an essential role in cancer and implication for immunotherapy
    Hui Wang, Qian Xu, Chanyuan Zhao, Ziqi Zhu, Xiaoqing Zhu, Junjie Zhou, Shu-Ming Zhang, Tiqun Yang, Biying Zhang, Jun Li et al. · 2020 · Journal for ImmunoTherapy of Cancer
  2. Immunity to Cancer Through Immune Recognition of Altered Self: Studies with Melanoma
    Jose Alejandro Guevara-Patino, Mary Jo Turk, Jedd D. Wolchok, Alan N. Houghton · 2003 · Advances in cancer research
  3. Molecular biology of epidermal growth factor receptor inhibition for cancer therapy
    Sabrina Oliveira, Paul M.P. van Bergen en Henegouwen, Gert Storm, Raymond Michel Schiffelers · 2006 · Expert Opinion on Biological Therapy
  4. T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival
    Sylvain Ladoire, Laurent Arnould, Grégoire Mignot, Lionel Apétoh, Cédric Rébé, F Martin, P. Fumoleau, Bruno P. Coudert, François Ghiringhelli · 2011 · British Journal of Cancer
  5. Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity
    Francesca Avogadri, Taha Merghoub, Maureen F. Maughan, Daniel Hirschhorn-Cymerman, John Morris, Erika Ritter, Robert A. Olmsted, Alan N. Houghton, Jedd D. Wolchok · 2010 · PLoS ONE
  6. Defucosylated Anti-CCR4 Monoclonal Antibody Exerts Potent ADCC against Primary ATLL Cells Mediated by Autologous Human Immune Cells in NOD/Shi-scid, IL-2Rγnull Mice In Vivo
    Asahi Ito, Takashi Ishida, Atae Utsunomiya, Fumihiko Sato, Fumiko Mori, Hiroki Yano, Atsushi Inagaki, Susumu Suzuki, Hisashi Takino, Masaki Ri et al. · 2009 · The Journal of Immunology
  7. Rituximab-CD20 Complexes Are Shaved from Z138 Mantle Cell Lymphoma Cells in Intravenous and Subcutaneous SCID Mouse Models
    Yongli Li, Michael E. Williams, John B. Cousar, Andrew W. Pawluczkowycz, Margaret A. Lindorfer, Ronald P. Taylor · 2007 · The Journal of Immunology
  8. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507
    Zhuo Zhang, Meili Zhang, Jeffrey V. Ravetch, Carolyn K. Goldman, Thomas A. Waldmann · 2003 · Blood
  9. Intimate Cell Conjugate Formation and Exchange of Membrane Lipids Precede Apoptosis Induction in Target Cells during Antibody-Dependent, Granulocyte-Mediated Cytotoxicity
    Heike Horner, Carola Frank, Claudia Dechant, Roland Repp, Martin J. Glennie, Martin Herrmann i, Bernhard Stockmeyer · 2007 · The Journal of Immunology
  10. The emerging importance of α-L-fucose in human breast cancer: a review.
    Jay J. Listinsky, Gene P. Siegal, Catherine M. Listinsky · 2011 · PubMed Central
  11. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies
    Magali Le Garff‐Tavernier, Julie Decocq, Christophe de Romeuf, Christophe Parizot, Charles‐Antoine Dutertre, Élise Chapiro, Frédéric Davi, Patrice Debré, Jean-François F. Prost, Jean‐Luc Teillaud et al. · 2010 · Leukemia
  12. In Vitro and In Vivo Models for Analysis of Resistance to Anticancer Molecular Therapies
    Roberta Rosa, Francesca Monteleone, Nicola Zambrano, Roberto Bianco · 2014 · Current Medicinal Chemistry
  13. Results of a Phase 1 Study of AME-133v (LY2469298), an Fc-Engineered Humanized Monoclonal Anti-CD20 Antibody, in FcγRIIIa-Genotyped Patients with Previously Treated Follicular Lymphoma
    Andres Forero, Sven de Vos, Brad L. Pohlman, Maksim A. Pashkevich, Damien M. Cronier, Nam Hoang Dang, Susan P. Carpenter, Barrett W. Allan, James G. Nelson, Christopher A. Slapak et al. · 2012 · Clinical Cancer Research
  14. Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti‐cancer antibodies: IUPHAR Review 18
    Sílvia Carvalho, Francesca Levi‐Schaffer, Michael Sela, Yosef Yarden · 2016 · British Journal of Pharmacology
  15. Natural killer (NK) cells and anti-tumor therapeutic mAb: unexplored interactions
    Simone Battella, Maria Christina Cox, Angela Santoni, Gabriella Palmieri · 2015 · Journal of Leukocyte Biology
  16. Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy
    Julia Niemann, Norman Woller, Jennifer Brooks, Bettina Fleischmann-Mundt, Nikolas Tim Martin, Arnold Kloos, Sarah Knocke, Amanda M. Ernst, Michael Peter Manns, Stefan Kubicka et al. · 2019 · Nature Communications
  17. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies
    Bernhard Stockmeyer, David Elsässer, Michael Dechant, Roland Repp, Martin Gramatzki, Martin J. Glennie, Jan G. J. van de Winkel, Thomas Valerius · 2001 · Journal of Immunological Methods
  18. Glycosylation Shapes the Efficacy and Safety of Diverse Protein, Gene and Cell Therapies
    Frances Rocamora, Angelo Gabriel Peralta, Seunghyeon Shin, James Sorrentino, Mina Ying Min Wu, Eric A. Toth, Thomas R. Fuerst, Nathan E. Lewis · 2023 · Biotechnology Advances
  19. Ocrelizumab: a step forward in the evolution of B-cell therapy
    Fariha Kausar, Khader N. Mustafa, Ghaleb Jalil Sweis, Ray Sawaqed, Khaldoon M. Alawneh, Rafah Salloum, Maria Elvira Badaracco, Timothy B. Niewold, Nadera Sweiss · 2009 · Expert Opinion on Biological Therapy
  20. The lymphocyte to monocyte ratio improves the IPI‐risk definition of diffuse large B‐cell lymphoma when rituximab is added to chemotherapy
    Alessandro Rambaldi, Cristina Boschini, Giuseppe Gritti, Federica Delaini, Elena Oldani, Andrea Rossi, Anna Maria Barbui, Daniele Caracciolo, Marco Ladetto, Angela Gueli et al. · 2013 · American Journal of Hematology
  21. Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy
    Lizet E. van der Kolk, A.J. Grillo-López, Johanna W. Baars, Marinus H. J. van Oers · 2003 · Leukemia
  22. Dual HER2-targeted approaches in HER2-positive breast cancer
    Eugene R. Ahn, Charles L. Vogel · 2011 · Breast Cancer Research and Treatment
  23. Targeting fatty acid oxidation enhances response to HER2-targeted therapy
    Ipshita Nandi, Linjia Ji, Harvey W. Smith, Daina Zofija Avizonis, Vasilios Papavasiliou, Cynthia A. Lavoie, Alain Pacis, Sherif Samer Attalla, Virginie Sanguin‐Gendreau, William J. Muller · 2024 · Nature Communications
  24. Expression and Modulation of the Human Immunoglobulin A Fc Receptor (CD89) and the FcR γ Chain on Myeloid Cells in Blood and Tissue
    R Hamre, Inger Nina Farstad, Petter Brandtzaeg, H. Craig Morton · 2003 · Scandinavian Journal of Immunology
  25. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn's disease
    Wouter M. Kooloos, Dirk J. de Jong, Tom W. J. Huizinga, Henk‐Jan Guchelaar · 2006 · Drug Discovery Today
  26. Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents
    Julien Jacques Max Boone, Jaishree Bhosle, Mike J. Tilby, John Anthony Hartley, Daniel Hochhauser · 2009 · Molecular Cancer Therapeutics
  27. Radioimmunotherapy of Solid Tumors: Searching for the Right Target
    Song Hong, George Sgouros · 2010 · Current Drug Delivery
  28. Obinutuzumab in hematologic malignancies: Lessons learned to date
    Tim Illidge, Christian Klein, Laurie Helen Sehn, Andrew John Davies, Gilles Salles, Guillaume Cartron · 2015 · Cancer Treatment Reviews
  29. Fibroblast growth factors in cancer: therapeutic possibilities
    Michael Jeffers, William J. LaRochelle, Henri S. Lichenstein · 2002 · Expert Opinion on Therapeutic Targets
  30. Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering
    Xiaojie Yu, Michael J. E. Marshall, Mark Steven Cragg, Max Crispin · 2017 · BioDrugs
  31. Harnessing the immune system via FcγR function in immune therapy: a pathway to next‐gen mAbs
    Alicia M. Chenoweth, Bruce D. Wines, Jessica C. Anania, Philip Mark Hogarth · 2020 · Immunology and Cell Biology
  32. Activating Fc Receptors Are Required for Antitumor Efficacy of the Antibodies Directed toward CD25 in a Murine Model of Adult T-Cell Leukemia
    Meili Zhang, Zhuo Zhang, Kayhan Garmestani, Carolyn K. Goldman, Jeffrey V. Ravetch, Martin W. Brechbiel, Jorge A. Carrasquillo, Thomas A. Waldmann · 2004 · Cancer Research
  33. Discovery of Fully Human Anti-MET Monoclonal Antibodies with Antitumor Activity against Colon Cancer Tumor Models In Vivo
    Edward Htun van der Horst, Lawrence Chinn, Min Wang, Timothy Velilla, Hoang Tran, Yarrow Madrona, Andrew Lam, May Ji, Timothy C. Hoey, Aaron K. Sato · 2009 · Neoplasia
  34. Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
    Stefania Bellone, Dana M. Roque, Emiliano Cocco, Sara Gasparrini, Ileana Bortolomai, Natália Buza, Maysa M Abu-Khalaf, D-A Silasi, Elena Ratner, Masoud Azodi et al. · 2012 · British Journal of Cancer
  35. A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy
    Xuejun Fan, Randall J. Brezski, Ming Fa, Hui Deng, Allison R. Greenplate, Anneliese O Gonzalez, William P. Dubinsky, William R. Strohl, Robert E. Jordan, Ningyan Zhang et al. · 2012 · Breast Cancer Research
  36. Modulation of antibody effector function
    John R. Desjarlais, Greg A. Lazar · 2011 · Experimental Cell Research
  37. Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin®): A case study
    Mark Daniel Pegram, Debbie Ngo · 2006 · Advanced Drug Delivery Reviews
  38. Rituximab-Mediated Cell Signaling and Chemo/Immuno-sensitization of Drug-Resistant B-NHL Is Independent of Its Fc Functions
    Mario I. Vega, Sara Huerta‐Yépez, Melisa A. Martinez-Paniagua, Bernardo Martínez-Miguel, Rogélio Hernández‐Pando, César Raúl González-Bonilla, Paul C. Chinn, Nabil Hanna, Kandasamy Hariharan, Ali R. Jazirehi et al. · 2009 · Clinical Cancer Research
  39. The cardiac safety of trastuzumab in the treatment of breast cancer
    Amy Jo Chien, Hope S. Rugo · 2010 · Expert Opinion on Drug Safety
  40. HER2 therapy. Small molecule HER-2 tyrosine kinase inhibitors
    Neil L. Spector, Wenle Xia, Iman A. El‐Hariry, Yossi Yarden, Sarah S. Bacus · 2007 · Breast Cancer Research
  41. Therapeutic efficacy of FcγRI/CD64-directed bispecific antibodies in B-cell lymphoma
    Jamie Honeychurch, Alison L. Tutt, Thomas Valerius, Ingmar Heijnen, Jan G. J. van de Winkel, Martin J. Glennie · 2000 · Blood
  42. One target, different effects: a comparison of distinct therapeutic antibodies against the same targets
    Hyunbo Shim · 2011 · Experimental & Molecular Medicine
  43. Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
    Joachim Diessner, Valentin S. Bruttel, Roland Gregor Stein, Evi Horn, Sebastian F. Häusler, J. Dietl, Arnd Hönig, Jörg Wischhusen · 2014 · Cell Death and Disease
  44. Effect of FCGR2A and FCGR3A variants on CLL outcome
    David Dornan, Olivia Spleiss, Ru-Fang Yeh, Guillemette Duchâteau-Nguyen, Annika Maria Dufour, Jianguo Zhi, Tadeusz Robak, Moiseev Si, Anna Dmoszyńska, Philippe Solal‐Céligny et al. · 2010 · Blood
  45. Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity
    Thomas F. Tedder, Aris Baras, Yan Xiu · 2006 · Springer Seminars in Immunopathology
  46. The mammary cellular hierarchy and breast cancer
    Samantha Richelle Oakes, David Gallego‐Ortega, Christopher John Ormandy · 2014 · Cellular and Molecular Life Sciences
  47. Effective lysis of lymphoma cells with a stabilised bispecific single‐chain Fv antibody against CD19 and FcγRIII (CD16)
    Joerg Bruenke, Karin Barbin, Susanne Kunert, Peter Lang, Matthias Manuel Pfeiffer, Kristin Stieglmaier, DIETRICH NIETHAMMER, Bernhard Stockmeyer, Matthias Peipp, Roland Repp et al. · 2005 · British Journal of Haematology
  48. Cripto
    Pei‐Xiang Xing, Xiu Feng Hu, Geoffrey A. Pietersz, Howard L. Hosick, Ian F. C. McKenzie · 2004 · Cancer Research
  49. Immunological ignorance of solid tumors
    Adrian F. Ochsenbein · 2005 · Springer Seminars in Immunopathology
  50. Tumor antigens for cancer immunotherapy: therapeutic potential of xenogeneic DNA vaccines
    Roopa Srinivasan, Jedd D. Wolchok · 2004 · Journal of Translational Medicine
  51. Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells
    Francesco Caiazza, Patricia M. McGowan, Maeve Mullooly, A Murray, Naoise C. Synnott, Norma O’Donovan, L. Flanagan, Christopher J. Tape, Gillian Murphy, John Paul Crown et al. · 2015 · British Journal of Cancer
  52. Molecular Pathways and Mechanisms of HER2 in Cancer Therapy
    Kanwal P. S. Raghav, Mark M. Moasser · 2022 · Clinical Cancer Research
  53. Focusing on NK cells and ADCC: A promising immunotherapy approach in targeted therapy for HER2-positive breast cancer
    Feifei Li, Sheng Liu · 2022 · Frontiers in Immunology
  54. Optimizing Therapeutic Antibody Function
    Etsuji Kaneko, Rinpei Niwa · 2010 · BioDrugs
  55. Combination of radiofrequency ablation and immunotherapy
    Francesco Fausto Fagnoni · 2007 · Frontiers in bioscience
  56. Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity
    Henri‐Alexandre Michaud, Jean‐François Eliaou, Virginie Lafont, Nathalie Bonnefoy, Laurent Gros · 2014 · OncoImmunology
  57. Trastuzumab: a novel standard option for patients with HER-2-positive advanced gastric or gastro-oesophageal junction cancer
    Alicia F. C. Okines, David Cunningham · 2012 · Therapeutic Advances in Gastroenterology
  58. A Hybrid Protein–Polymer Nanoworm Potentiates Apoptosis Better than a Monoclonal Antibody
    Suhaas Rayudu Aluri, Pu Shi, Joshua A. Gustafson, Wan Wang, Yi-An Lin, Honggang Cui, Shuanglong Liu, Peter S. Conti, Zibo Li, Peisheng Hu et al. · 2014 · ACS Nano
  59. Antibodies targeting sialyl Lewis A mediate tumor clearance through distinct effector pathways
    Polina Weitzenfeld, Stylianos Bournazos, Jeffrey V. Ravetch · 2019 · Journal of Clinical Investigation
  60. Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations
    Alwin S. Jeyakumar, Tallal Younis · 2012 · Clinical Medicine Insights Oncology
  61. Role of receptor tyrosine kinases in gastric cancer: New targets for a selective therapy
    JC Becker · 2006 · World Journal of Gastroenterology
  62. TM4SF1: a new vascular therapeutic target in cancer
    Chi‐Iou Lin, Anne Merley, Tracey E. Sciuto, Dan Li, Ann M. Dvořàk, Juan M. Melero‐Martin, Harold F. Dvorak, Shou-Ching Shih Jaminet · 2014 · Angiogenesis
  63. Experimentally induced liver metastases from colorectal cancer can be prevented by mononuclear phagocyte-mediated monoclonal antibody therapy
    Gerben J. van der Bij, Marijn Bögels, Marielle A. Otten, Steven J. Oosterling, Peter J.K. Kuppen, Sybren Meijer, Robert H.J. Beelen, Marjolein van Egmond · 2010 · Journal of Hepatology
  64. Cancer therapeutic antibodies come of age: Targeting minimal residual disease
    Tsipi Ben-Kasus, Bilha Schechter, Michael Sela, Yosef Yarden · 2007 · Molecular Oncology
  65. Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2–positive breast cancer
    Xavier B. Pivot, Mark Daniel Pegram, Javier Cortés, Diana Lüftner, Gary H. Lyman, Giuseppe Curigliano, Igor Bondarenko, Ye Chan Yoon, Younsoo Kim, Chul Kim · 2019 · European Journal of Cancer
  66. Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs
    Gigi N.C. Chiu, Lincoln Edwards, Anita I. Kapanen, Melina M. Malinen, Wieslawa H. Dragowska, Corinna Warburton, Ghania Chikh, Karen Y.Y. Fang, Sophia Tan, Jonathan Sy et al. · 2007 · Molecular Cancer Therapeutics
  67. Charge variant analysis of proposed biosimilar to Trastuzumab
    Dakshinamurthy, Pravinkumar, Mukunda, Pavithra, Prasad Kodaganti, Bhargav, Shenoy, Bharath Ravindra, Natarajan, Bairavabalakumar, Maliwalave, Amol, Halan, Vivek, Murugesan, Sathyabalan, Maity, Sunit · 2017 · Biologicals
  68. CD16+ fibroblasts foster a trastuzumab-refractory microenvironment that is reversed by VAV2 inhibition
    Xinwei Liu, Yiwen Lu, Jingying Huang, Yue Xing, Huiqi Dai, Liling Zhu, Shunrong Li, Jingwei Feng, Boxuan Zhou, Jiaqian Li et al. · 2022 · Cancer Cell
  69. Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu
    Joan T. Garrett, Sharad V. Rawale, Stephanie D. Allen, Gary S. Phillips, Guido Forni, John C Morris, Pravin T. P. Kaumaya · 2007 · The Journal of Immunology
  70. Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy
    Qun Zhou, Aleksandra J. Gil-Krzewska, Giovanna Peruzzi, Francisco Borrego · 2013 · Clinical & Experimental Immunology
  71. Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation
    Yun Shi, Xuejun Fan, Weixu Meng, Hui Deng, Ningyan Zhang, Zhiqiang An · 2014 · Breast Cancer Research
  72. Anti-BR3 antibodies: a new class of B-cell immunotherapy combining cellular depletion and survival blockade
    Wei Yu Lin, Qian Gong, Dhaya Seshasayee, Zhonghua Lin, Qinglin Ou, Shiming Ye, Eric Suto, Jean Shu, Wyne Pun Lee, Chingwei V. Lee et al. · 2007 · Blood
  73. Targeted cancer therapies based on antibodies directed against epidermal growth factor receptor: status and perspectives
    Zhenping Zhu · 2007 · Acta Pharmacologica Sinica
  74. Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach
    Tim J. A. Dekker, Susan ter Borg, Gerrit K. J. Hooijer, Sybren Lodewijk Meijer, Jelle Wesseling, James E. Boers, Ed M. D. Schuuring, Joost Bart, Joost van Gorp, Wilma E. Mesker et al. · 2012 · Breast Cancer Research
  75. Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics
    Lian Li, Jiyuan Yang, Jiawei Wang, Jindŕich Kopec̆ek · 2018 · ACS Nano
  76. HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies
    Lucía Gandullo‐Sánchez, Emily Capone, Alberto Ocaña, Stefano Iacobelli, Gianluca Sala, Atanasio Pandiella · 2020 · EMBO Molecular Medicine
  77. Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment
    Holbrook E K Kohrt, Narendiran Rajasekaran, Cariad Chester, Atsushi Yonezawa, Xing Zhao · 2015 · ImmunoTargets and Therapy
  78. Emerging perspectives in epidermal growth factor receptor targeting in head and neck cancer
    Seungwon Kim, Jennifer Rubin Grandis, Alessandra Rinaldo, Robert Paul Takes, Alfio Ferlito · 2008 · Head & Neck
  79. Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy
    Josep Lluís Parra-Palau, Beatriz Morancho, Vicente Peg, Marta Escorihuela, Maurizio Scaltriti, Rocío Vicario, Mariano F. Zacarías Fluck, Kim Pedersen, Atanasio Pandiella, Paolo Giovanni Nuciforo et al. · 2014 · JNCI Journal of the National Cancer Institute
  80. Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.
    Deborah J. L. Wong, Sara Alsterlind Hurvitz · 2014 · Europe PMC (PubMed Central)
  81. Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting
    Saskia Meyer, Maaike Nederend, J.H. Marco Jansen, Karli R. Reiding, Shamir R. Jacobino, Jan Meeldijk, Niels Bovenschen, Manfred Wuhrer, Thomas Valerius, Ruud Ubink et al. · 2015 · mAbs
  82. Anti‐retroviral antibody FcγR‐mediated effector functions
    Stylianos Bournazos, Jeffrey V. Ravetch · 2017 · Immunological Reviews
  83. Synergy between Th1 and Th2 responses during Mycobacterium tuberculosis infection: A review of current understanding
    Fekadu Abebe · 2019 · International Reviews of Immunology
  84. Unraveling the Complex Relationship Between Cancer Immunity and Autoimmunity: Lessons from Melanoma and Vitiligo
    Hiroshi Uchi, Rodica Stan, Mary Jo Turk, Manuel E. Engelhorn, Gabrielle A. Rizzuto, Stacie M. Goldberg, Jedd D. Wolchok, Alan N. Houghton · 2006 · Advances in immunology
  85. Cholesterol depletion inhibits src family kinase‐dependent calcium mobilization and apoptosis induced by rituximab crosslinking
    Tammy L. Unruh, Haidong Li, Cathlin M. Mutch, Neda Shariat, Lana Grigoriou, Ratna Sanyal, Christopher B. Brown, Julie P. Deans · 2005 · Immunology
  86. Anti‐HER‐3 MAbs inhibit HER‐3‐mediated signaling in breast cancer cell lines resistant to anti‐HER‐2 antibodies
    Edward Htun van der Horst, Marta Murgia, Martin Treder, Axel Ullrich · 2005 · International Journal of Cancer
  87. Trastuzumab as Adjuvant Therapy for Early Breast Cancer: The Importance of Accurate Human Epidermal Growth Factor Receptor 2 Testing
    David G. Hicks, Swati Kulkarni · 2008 · Archives of Pathology & Laboratory Medicine
  88. Three-colour flow cytometric method to measure antibody-dependent tumour cell killing by cytotoxicity and phagocytosis
    Marguerite G. Bracher, Hannah Jane Gould, Brian J. Sutton, David Dombrowicz, Sophia N. Karagiannis · 2007 · Journal of Immunological Methods
  89. The novel tribody [(CD20)2xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells
    Pia Glorius, Anne Baerenwaldt, Christian Kellner, Matthias Staudinger, Michael Dechant, Martina Beate Stauch, Frank J M Beurskens, Paul W.H.I. Parren, Jan G. J. van de Winkel, Thomas Valerius et al. · 2012 · Leukemia
  90. Current treatment of early breast cancer: adjuvant and neoadjuvant therapy
    Elizabeth Miller, Hee Jin Lee, Amriti R. Lulla, Liz Hernandez, Prashanth Ravishankar Gokare, Bora Lim · 2014 · F1000Research
  91. The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy
    François Ghiringhelli, Lionel Apétoh · 2013 · Expert Review of Clinical Immunology
  92. Direct Effect of Rituximab in B-Cell–Derived Lymphoid Neoplasias: Mechanism, Regulation, and Perspectives
    Christine Bezombes, Jean‐Jacques Fournié, Guy Laurent · 2011 · Molecular Cancer Research
  93. Antibody Targeting to a Class I MHC-Peptide Epitope Promotes Tumor Cell Death
    Vaughan Wittman, David Woodburn, Tiffany Tuyen Minh Nguyen, Francisca A. Neethling, Stephen E. Wright, Jon A. Weidanz · 2006 · The Journal of Immunology
  94. Cancer Immunotherapy and Preclinical Studies: Why We Are Not Wasting Our Time with Animal Experiments
    Karin Schreiber, Donald A. Rowley, Gert Riethmüller, Hans Wilhelm Schreiber · 2006 · Hematology/Oncology Clinics of North America
  95. The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
    H. Maadi, Babak Nami, Junfeng Tong, Gina Li, Zhixiang Wang · 2018 · BMC Cancer
  96. Targeting the Antibody Checkpoints to Enhance Cancer Immunotherapy–Focus on FcγRIIB
    Ingrid Teige, Linda Mårtensson, Björn Frendéus · 2019 · Frontiers in Immunology
  97. Fc Receptors as Adaptive Immunoreceptors
    Marc Daëron · 2014 · Current topics in microbiology and immunology
  98. Action and resistance of monoclonal CD20 antibodies therapy in B-cell Non-Hodgkin Lymphomas
    David Pérez-Callejo, Julia González‐Rincón, Antonio Sánchez, Mariano Provencio, Margarita Sánchez‐Beato · 2015 · Cancer Treatment Reviews
  99. Anti-CD20 therapy induces a memory Th1 response through the IFN-γ/IL-12 axis and prevents protumor regulatory T-cell expansion in mice
    Claire Deligne, Amina Metidji, Wolf H. Fridman, Jean‐Luc Teillaud · 2014 · Leukemia
  100. Glycoengineering Chinese hamster ovary cells: a short history
    Donini, Roberto, Haslam, Stuart M., Kontoravdi, Cleo · 2021 · Biochemical Society Transactions